-

EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc. – APLT

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.

On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the Company's ACTION-Kids study evaluating the Company's AT-007 product for the treatment of galactosemia. The FDA cited the need for additional technical information related to ensuring that every participant in the study has access to the drug's benefits.

On this news, Applied Therapeutics’ stock price fell $3.53 per share, or 12%, to close at $25.71 per share on August 17, 2020.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Applied Therapeutics’ investors. If you purchased shares of Applied Therapeutics, please visit the firm’s website at http://www.rosenlegal.com/cases-register-1928.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Rosen Law Firm

NASDAQ:APLT

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Social Media Profiles
More News From Rosen Law Firm

Rosen Law Firm Urges PomDoctor Ltd. (NASDAQ: POM) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025. PomDoctor describes itself as a “leading online medical services platform for chronic diseases in China.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations...

Rosen Law Firm Encourages GSI Technology Inc. Investors to Inquire About Securities Class Action Investigation – GSIT

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public. So What: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen...

Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025. Ultragenyx describes itself as a “biopharmaceutical company focused on rare and ultrarare genetic disorders.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investig...
Back to Newsroom